Literature DB >> 34907463

[Treatment of advanced hormone-sensitive prostate cancer using degarelix].

Nikolaos Pyrgidis1, Georgios Hatzichristodoulou1, Ioannis Sokolakis2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34907463     DOI： 10.1007/s00120-021-01735-x

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  10 in total

1.  Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.

Authors:  Lanting Lu; Jaime Peters; Chris Roome; Ken Stein
Journal:  BJU Int       Date:  2011-08-23       Impact factor: 5.588

Review 2.  Degarelix: a review of its use in patients with prostate cancer.

Authors:  Natalie J Carter; Susan J Keam
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

3.  Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.

Authors:  Laurence Klotz; Kurt Miller; E David Crawford; Neal Shore; Bertrand Tombal; Cathrina Karup; Anders Malmberg; Bo-Eric Persson
Journal:  Eur Urol       Date:  2014-01-09       Impact factor: 20.096

Review 4.  Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.

Authors:  Yuanshan Cui; Huantao Zong; Huilei Yan; Nan Li; Yong Zhang
Journal:  Urol Int       Date:  2014-03-01       Impact factor: 2.089

Review 5.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

Authors:  Philip Cornford; Roderick C N van den Bergh; Erik Briers; Thomas Van den Broeck; Marcus G Cumberbatch; Maria De Santis; Stefano Fanti; Nicola Fossati; Giorgio Gandaglia; Silke Gillessen; Nikolaos Grivas; Jeremy Grummet; Ann M Henry; Theodorus H van der Kwast; Thomas B Lam; Michael Lardas; Matthew Liew; Malcolm D Mason; Lisa Moris; Daniela E Oprea-Lager; Henk G van der Poel; Olivier Rouvière; Ivo G Schoots; Derya Tilki; Thomas Wiegel; Peter-Paul M Willemse; Nicolas Mottet
Journal:  Eur Urol       Date:  2020-10-07       Impact factor: 20.096

6.  Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy.

Authors:  Alexander C Fanaroff; Shuang Li; Guillaume Marquis-Gravel; Jay Giri; Renato D Lopes; Jonathan P Piccini; Tracy Y Wang
Journal:  Circ Cardiovasc Interv       Date:  2021-12-21       Impact factor: 6.546

7.  Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

Authors:  Neal D Shore; Fred Saad; Michael S Cookson; Daniel J George; Daniel R Saltzstein; Ronald Tutrone; Hideyuki Akaza; Alberto Bossi; David F van Veenhuyzen; Bryan Selby; Xiaolin Fan; Vicky Kang; Jackie Walling; Bertrand Tombal
Journal:  N Engl J Med       Date:  2020-05-29       Impact factor: 91.245

8.  Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases.

Authors:  Gincy George; Hans Garmo; Lucie-Marie Scailteux; Frédéric Balusson; Greet De Coster; Harlinde De Schutter; Josephina G Kuiper; Emmanuel Oger; Julie Verbeeck; Mieke Van Hemelrijck
Journal:  Int J Cancer       Date:  2020-11-23       Impact factor: 7.396

Review 9.  The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.

Authors:  Reza Sari Motlagh; Mohammad Abufaraj; Keiichiro Mori; Abdulmajeed Aydh; Pawel Rajwa; Satoshi Katayama; Nico C Grossmann; Ekaterina Laukhtina; Hadi Mostafai; Benjamin Pradere; Fahad Quhal; Pierre I Karakiewicz; Dmitry V Enikeev; Shahrokh F Shariat
Journal:  Eur Urol Oncol       Date:  2021-07-21

Review 10.  Degarelix for treating advanced hormone-sensitive prostate cancer.

Authors:  Friedemann Zengerling; Joachim J Jakob; Stefanie Schmidt; Joerg J Meerpohl; Anette Blümle; Christine Schmucker; Benjamin Mayer; Frank Kunath
Journal:  Cochrane Database Syst Rev       Date:  2021-08-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.